HIV/Hepatitis C Virus-coinfected patients and cirrhosis: How to diagnose it and what to do next?

Clinical Infectious Diseases

Volumn 58, Issue 6, 2014, Pages 840-847

  Martel Laferrière, Valérie ^a   Wong, Michael ^b   Dieterich, Douglas T ^c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

cirrhosis; hepatocellular carcinoma; HIV HCV coinfection; liver failure; varices

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; BOCEPREVIR; COBICISTAT; DACLATASVIR; DARUNAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; GAMMA GLUTAMYLTRANSFERASE; INDINAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RALTEGRAVIR; RIBAVIRIN; RILPIVIRINE; SAQUINAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; TENOFOVIR; TIPRANAVIR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; APRI SCORE; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL PERITONITIS; DISEASE SEVERITY; EARLY DIAGNOSIS; EMPOWERMENT; ESOPHAGUS VARICES; FIB 4 SCORE; FIBROMETER; FIBROSPECT; FIBROTEST; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPASCORE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT; LIVER TOXICITY; LIVER TRANSPLANTATION; MEDICAL SPECIALIST; MIXED INFECTION; MORBIDITY; MORTALITY; NON INVASIVE PROCEDURE; PATIENT COUNSELING; PATIENT REFERRAL; PRIORITY JOURNAL; RISK MANAGEMENT; SCREENING; SECONDARY PREVENTION; THROMBOCYTE COUNT; TRANSIENT ELASTOGRAPHY; VACCINATION; COINFECTION; HIV INFECTIONS; LIVER NEOPLASMS; VIROLOGY;

COINFECTION; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS;

EID: 84895730444     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit714     Document Type: Article

References (46)

1. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. AIDS 2010; 24:1537-48.
2. Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007; 21:2209-16.
3. Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 2013; 57:249-57.
4. Smith BD, Morgan RL, Beckett GA; Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61(RR-4): 1-32.
5. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009; 49:1017-44.
6. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-9.
7. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646-9.
8. Freeman RB Jr, Wiesner RH, Harper A, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002; 8:851-8.
9. Singal AG, Thomassen LV, Gretch DR, Shuhart MC. Use of the AST to platelet ratio index in HCV/HIV co-infected patients. Aliment Pharmacol Ther 2011; 33:566-77.
10. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-26.
11. Cacoub P, Carrat F, Bedossa P, et al. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study - ANRS HC02. J Hepatol 2008; 48:765-73.
12. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-25.
13. Poynard T, Munteanu M, Deckmyn O, et al. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. BMC Gastroenterol 2011; 11:39.
14. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51:1867-73.
15. Patel K, Gordon SC, Jacobson I, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004; 41:935-42.
16. Cales P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42:1373-81.
17. Cales P, Halfon P, Batisse D, et al. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. J Hepatol 2010; 53:238-44.
18. Stebbing J, Farouk L, Panos G, et al. A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol 2010; 44:214-9.
19. Kirk GD, Astemborski J, Mehta SH, et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis 2009; 48: 963-72.
20. Smith JO, Sterling RK. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther 2009; 30:557-76.
21. Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology 2010; 51:1445-9.
22. Moyer VA. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 159: 210-8.
23. Bani-Sadr F, Carrat F, Rosenthal E, et al. Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment. Clin Infect Dis 2005; 41: 1806-9.
24. PEGASYS (peginterferon alfa-2a) injection for subcutaneous use: full prescribing information. September 2011. Genentech, Inc. http:// www.accessdata.fda.gov/drugsatfda-docs/label/2011/103964s5204lbl. pdf. Accessed 7 November 2013.
25. PegIntron (Peginterferon alfa-2b) injection, powder for solution for subcutaneous use: full prescribing information. December 2011. Schering Corporation, a subsidiary of Merck & Co., Inc. http://www.access data.fda.gov/drugsatfda-docs/label/2011/103949s5217s5222lbl.pdf. Accessed 7 November 2013.
26. Incivek (telaprevir): full prescribing information. October 2013. Vertex Pharmaceuticals Incorporated http://pi.vrtx.com/files/uspi-telaprevir. pdf. Accessed 7 November 2013.
27. Victrelis (boceprevir) capsules for oral use: full prescribing information. September 2013. Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. http://www.merck.com/product/usa/pi-circulars/v/victrelis/ victrelis-pi.pdf. Accessed 7 November 2013.
28. Ouwerkerk-Mahadevan S, Simion A, Spittaels K, Beaumont-Mauviel M. Pharmacokinetics of Simeprevir (TMC 435) in volunteers with moderate or severe hepatic impairment. J Hepatol 2013; 58(suppl 1): S365.
29. Bifano M, Sevinsky H, Persson A, et al. Single-dose pharmacokinetics of daclatasvir (DCV; BMS-790052) in subjects with hepatic impairment compared with healthy subjects. Hepatology 2011; 54(S1): 252A.
30. Lawitz E, Rodriguez-Torres M, Cornpropst M, et al. The Effect of hepatic impairment on the safety, pharmacokinetics, and antiviral activity of GS-7977 in hepatitis C infected subjects treated for seven days. J Hepatol 2012; 56(suppl 2): S445-6.
31. Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308:370-8.
32. McGovern BH, Golan Y, Lopez M, et al. The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients. Clin Infect Dis 2007; 44:431-7.
33. Bridges CB, Woods L, Coyne-Beasley T. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older - United States, 2013. MMWR Surveill Summ 2013; 62(suppl 1): 9-19.
34. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46:922-38.
35. Berretta M, Garlassi E, Cacopardo B, et al. Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. Oncologist 2011; 16:1258-69.
36. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020-2.
37. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908-43.
38. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49:2087-107.
39. European Association for the Study of the Liver . EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53:397-417.
40. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35:716-21.
41. Bajaj JS, Saeian K, Schubert CM, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009; 50:1175-83.
42. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008; 8:355-65.
43. Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18:716-26.
44. Murray KF, Carithers RL Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005; 41:1407-32.
45. Ragni MV, Eghtesad B, Schlesinger KW, Dvorchik I, Fung JJ. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl 2005; 11:1425-30.
46. Subramanian A, Sulkowski M, Barin B, et al. MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology 2010; 138:159-64.